New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease pat

AbbVie's dividend yield has declined because its share price has risen faster than its dividend. The

John Moolenaar asks the US Defense Department to add 58 Chinese schools and 62 technology labs to it

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 8.13% on an annualized basis

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target f

These companies might bend during a downturn, but they won't break.

Three of these six income stocks beat current Treasury bill yields, but a higher number on the label

Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targ

Bell Asset Management Ltd cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 48.2% during the

GAMMA Investing LLC raised its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 10.4% during the un

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the pric

ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non

While AI investing initially centered on hyperscalers and chips, the opportunity has been broadening

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises

AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab

Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises th

A fat dividend yield means nothing if the cash runs dry before the check clears. These five companie

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a

Treasuries now offer a yield that dividend investors once bragged about, which raises a question mos

These stocks have tremendous businesses, and their valuations are incredibly low.

One analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the

Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of th

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

AbbVie has generated solid double-digit growth in its most recent quarters. Additional approvals for

When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible momen

Scotiabank analyst Louise Chen maintains AbbVie (NYSE:ABBV) with a Sector Outperform and raises t

AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bough

AbbVie (NYSE: ABBV - Get Free Report) issued an update on its third quarter 2026 earnings guidance o

AbbVie (NYSE: ABBV - Get Free Report) updated its third quarter 2026 earnings guidance on Tuesday mo

AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior

Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for ​p

AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improveme

[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline resul

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today positive topline results from the Ph

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrat

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NY

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is

Park National Corp OH trimmed its stake in AbbVie Inc. (NYSE: ABBV) by 6.6% in the third quarter, ac

Eastern Bank reduced its position in AbbVie Inc. (NYSE: ABBV) by 1.4% during the undefined quarter,

MassMutual Private Wealth and Trust FSB decreased its holdings in AbbVie Inc. (NYSE: ABBV) by 5.2% i

Violich Capital Management Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 1.8% in th

Friday's regular session has eight sectors higher and three lower, with growth sectors holding t

AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Vit

AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, high

CNBC traders picked Eaton, SpaceX, AbbVie and AMD, citing analyst support, SpaceX’s Starship launch

AbbVie (NYSE:ABBV) today announced that detailed results from the multiple ascending dose (MAD) part